期刊文献+

妇科恶性肿瘤化疗药物剂量计算的现状 被引量:1

下载PDF
导出
摘要 通常药物治疗的剂量范围是指产生疗效与发生不可预知毒性的剂量范围。在肿瘤的化学治疗中.化疗药物治疗的剂量范围十分狭窄。肿瘤的化疗已有半个多世纪的历史,化疗药物的毒性大、安全系数较小,而且在人体代谢和排泄个体差异大.因此可能导致个体间不同的治疗效果。所以有必要根据药物的药物代谢动力学设计个体化的理想给药方案.从而达到最大耐量、取得最大疗效、避免不可耐受的毒性。现就妇科恶性肿瘤化疗药物剂量计算的研究现状综述如下。
作者 丁丁 孔为民
出处 《北京医学》 CAS 2012年第2期128-130,共3页 Beijing Medical Journal
  • 相关文献

参考文献18

  • 1Reilly JJ, Workman P. Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations. Cancer Chemotherapy Pharmacol, 1993,32:411-418.
  • 2Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res,1958,18:853-856.
  • 3Freireich E J, Gehan EA, Rail DP, et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemotherapy Rep,1966, 50:219-244.
  • 4宋坤,孔北华.卵巢上皮性癌治疗的随机对照临床试验研究进展[J].中国实用妇科与产科杂志,2007,23(1):17-21. 被引量:8
  • 5连利娟,林巧雅.妇科肿瘤学.4版.北京:人民卫生出版社,2006:410-413.
  • 6Gurney H. Dose calculation of anticancer drngs:a review of the current practice and introduction of an alternative. J Clin Oncol, 1996,14:2590-2611.
  • 7Gurney H. How to calculate the dose of chemotherapy. Br J Can cer,2002,86:1297-1302.
  • 8Collins JM, Zaharko DS, Dedrick RL, et al. Potential roles for prec|inical pharmacology in phase I clinical trials. Cancer Treat Rep, 1986,70:73-80.
  • 9Calvert AH, Newel1 DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renalfunction. Clin 0nco1,1989,7:1748.
  • 10周际吕.实用肿瘤外科学.北京:人民卫生出版社.1999:333-338.

二级参考文献41

  • 1Hermes A, Bergman B, Bremnes R, et al.Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer:a randomized phase Ⅲ trial[J].J Clin Oncol,2008,26(26): 4 261 - 4 267.
  • 2Tas F, Derin D, Guney N, et al. Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum- sensitive epithelial ovarian cancer[J]. Int J Clin Oncol,2008,13 (4) : 330 - 334.
  • 3Hirseh FR, Varella-Garcia. M, Dziadziuszko R, et al. Fluorescence in situ hybridization subgroup analysis of tribute, a phase Ⅲ trial of erlotinib plus carboplatin and paelitaxel in non-small cell lung cancer[J]. Clin Cancer Res,2008,14 (19) : 6 317 - 6 323.
  • 4Folprecht G, Kohne CH, Lutz MP, et al. Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer[J]. Cancer Treat Res,2007,134:425 - 440.
  • 5Capdevila L Elez E, Peraha S, et al. Oxaliplatin - based chemotherapy in the management of colorectal cancer[J]. Expert Rev Anticancer Ther, 2008,8(8): 1 223 - 1 236.
  • 6Belani CP. Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma [J]. Semin Oncol,2004,31 (6 Suppl 14): 25 - 33.
  • 7Oshita F, Saito H, Yamada K, et al. Feasible combination chemotherapy with nedaplatin and irinotecan for patients with non-small cell lung cancer and multiple high-risk factors[J].J Exp Ther Oncol, 2007,6 (3): 251 - 256.
  • 8McKeage MJ. Lobaplatin: a new antitumour platinum drag[J]. Expert Opin Investig Drugs, 2001, 10(1 ) : 119 - 128.
  • 9McKeage MJ. Satraplatin in hormone-refractory prostate cancer and other turnout types: pharmacological properties and clinical evaluation[J]. Drags,2007, 67(6): 859 - 869.
  • 10Akaboshi M, Kawai K, Ujeno Y, et al. Binding characteristics of (R) - 2 - aminomethylpyrrolidine ( 1, 1- (-)- )-2- platin urn(11) to DNA, RNA and protein molecules in HeLa cells and its lethal effect: comparison with cis- and trans- diamminedichloroplatinums(Ⅱ) [J]. Jpn J Cancer Res, 1994, 85(1): 106 - 111.

共引文献56

同被引文献5

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部